Major Depressive Disorder & Treatment-Resistant Depression

Why this condition is marked promising

Depression — particularly treatment-resistant depression (TRD) — is the most mature clinical indication for psilocybin-assisted therapy. Open-label feasibility work was followed by randomised trials showing large effect sizes versus waitlist or low-dose controls, with some cohorts retaining benefit at longer follow-up.

What the evidence currently supports

• Rapid reductions in depressive symptom scores after one or two supervised dosing sessions with psychological support.
• Signals of durability lasting weeks to months in subsets of participants.
• Neuroimaging correlates involving shifts in rigid self-referential network dynamics, often discussed in relation to the default mode network.

Important limitations

• Sample sizes remain modest relative to conventional antidepressant programmes.
• Blinding is difficult; expectancy effects are a genuine methodological concern.
• Not everyone responds, and adverse psychological experiences can occur even in screened settings.
• Concurrent serotonergic antidepressants may attenuate subjective effects; medication washout protocols in trials are specialised and must be clinician-managed.

Practical reading for clinicians and patients

Treat current findings as strong early clinical evidence, not as a guarantee of cure. PSILORIS categorises depression as promising because replicated controlled signals exist, while still requiring careful consent, screening, and integration support.